Sigma Healthcare Limited Overview
Sigma Healthcare is Australia's largest vertically integrated pharmacy group. It combines the country's dominant discount pharmacy franchise, Chemist Warehouse, with a full-line national pharmaceutical wholesale and distribution platform. The February 2025 reverse merger turned a low-margin wholesaler into a franchisor-wholesaler earning a normalised EBIT margin of about 10%. FY26 revenue was A$10.8bn and normalised EBIT was A$1.09bn.
The Chemist Warehouse branded network generated A$10.2bn of Australian store sales across 561 stores in FY26. International store sales across New Zealand, Ireland, the UAE and (from late 2026) the United Kingdom reached a further A$1.6bn. The group also franchises the Amcal and Discount Drug Stores banners and supplies independent pharmacies.
Its moat rests on three things: purchasing scale, a low-cost warehouse supply chain moving more than 579 million units a year, and an owned and exclusive label portfolio approaching A$1bn. Founder control remains high, at roughly 48% of shares held by the Verrocchi and Gance families.
Company's own description
In its FY26 results materials, Sigma describes itself as an integrated healthcare business. Value creation is framed around four pillars:
-
Domestic — Chemist Warehouse branded network sales.
-
International — store sales outside Australia.
-
Product Differentiation — owned and exclusive label sales.
-
Operating Leverage — delivering benefits from scale.
CEO Vikesh Ramsunder said FY26 shows Sigma is "not simply larger" after the merger but "structurally stronger" (FY26 ASX release, 27 August 2026).
Sigma's market profile describes a group that franchises retail pharmacies in Australia and internationally. As a full-line wholesaler and distributor, it supplies prescription medicines, including Pharmaceutical Benefits Scheme (PBS) medicines, over-the-counter (OTC) products and front-of-store products to more than 3,500 pharmacy customers. Those customers include its own retail network and independent pharmacies (ASX company description via HotCopper).
Independent characterisation
Sigma operates a three-layer model.
Layer 1 — Franchisor and brand owner. Australian law restricts pharmacy ownership to registered pharmacists. Sigma therefore does not own most Australian stores. It franchises them and earns revenue from three sources:
-
wholesale sale of goods to franchisees, which is the dominant line;
-
franchise and marketing fees;
-
margin on owned and exclusive label products.
This is why statutory revenue (A$10.8bn) is close to Australian network sales (A$10.2bn). The key distinction is that Sigma books the wholesale value of goods sold to stores, not consumer retail sales.
Layer 2 — National wholesaler and distributor. Legacy Sigma runs 11 Australian distribution centres with more than 240,000 square metres of capacity. It completes more than 600,000 deliveries a year and distributed more than 579 million units in FY26, up 6.5%. It serves the Chemist Warehouse network, the Amcal and Discount Drug Stores networks, and independent pharmacies. It also provides third-party logistics (3PL) and receives Community Service Obligation (CSO) funding for PBS distribution. The FY26 results presentation records Sigma ranked No.1 wholesaler in an Advantage Group supplier survey.
Layer 3 — International retail. Chemist Warehouse stores operate in New Zealand (about 70 network stores at 1H26), Ireland (17), the UAE (2 stores plus online since October 2025), and the UK (Greenlight JV, first stores expected by December 2026). Bricks-and-mortar stores in China are being progressively closed (announced August 2025). International stores are typically owned or majority-owned rather than franchised. This explains the International segment's much higher gross margin (30.6% in FY26).
Revenue model mix
| Revenue type | Description | Estimated weight | Basis |
|---|---|---|---|
| Product sales (wholesale to franchisees and independents) | PBS and non-PBS prescriptions, OTC, vitamins, beauty and front-of-store, sold at wholesale | Dominant (>90% of revenue) | Derived from segment structure. Exact split not publicly disclosed. |
| Product sales (owned international stores) | Retail sales at company-controlled stores in NZ, Ireland, UAE and UK | c. 3.9% (International segment revenue A$421.4m / A$10.8bn, FY26) | FY26 release |
| Franchise and marketing fees | Fees from franchisees for brand, systems and marketing | — | — |
| Services / 3PL / CSO | Logistics services and government CSO funding | — | — |
| Subscription / licensing | Brand and IP licensing (for example, the UK Greenlight JV licence) | Immaterial at present | 4 May 2026 release |
Value chain position
Sigma sits between pharmaceutical and consumer-health manufacturers (originator and generic pharma, vitamin, beauty and fragrance suppliers) and community pharmacies and end consumers. It controls procurement, warehousing, distribution, franchise retail branding and some product development through its owned and exclusive labels. Supplier support (rebates and promotional funding) is a material gross margin driver. The 1H26 and FY26 presentations both cite "mix and supplier support" as margin contributors.
Customer types and end-markets
Consumers: via Chemist Warehouse, My Chemist, Amcal, Discount Drug Stores and online channels. Categories include dispensary (PBS and private scripts, notably GLP-1 weight-loss medicines), vitamins and supplements, cosmetics, fragrance, personal care and baby.
Franchisee pharmacists: 881 franchise stores across Australia at FY25.
Independent pharmacies: as wholesale and 3PL customers.
Government: as funder of the PBS and CSO.
Suppliers: buying promotional, retail media and data services. This is an emerging area; no specific disclosure was found.
Strategy
Stated strategy
Sigma's FY26 materials organise strategy around four value-creation pillars:
-
Domestic: grow the Australian CW-branded network (24 stores in FY26; 13 planned for 1H27) and LFL sales.
-
International: expand CW in New Zealand, Ireland, the UAE and the UK; exit China.
-
Product Differentiation: owned and exclusive label (c. A$1.0bn; 470+ new lines in FY26).
-
Operating Leverage: scale benefits in distribution and synergies (A$100m a year by FY29).
The FY27 agenda, as articulated in the FY26 release, is to grow the network, drive operating leverage, enhance product differentiation, and convert the platform into sustainable profit and cash generation.
Initiatives register (last 24 months)
| Initiative | Date | Description / targets | Status | Source |
|---|---|---|---|---|
| Merger integration and synergies | August 2025 (upgrade) | Target raised from A$60m to A$100m a year by FY29 | A$13.0m delivered in 1H26; A$32.6m in FY26 | FY25 release; FY26 release |
| DC network rationalisation | FY26–FY27 | South Guildford (WA) closed May 2026; Port Adelaide (SA) closing 1Q FY27; e-commerce DC consolidated; support centres merged at Preston | In progress | FY26 presentation |
| China retail exit | Announced August 2025 | Progressive closure of CW bricks-and-mortar stores over two years | In progress | FY25 release |
| UK market entry (Greenlight JV) | MoU 4 May 2026 | CW brand and IP licence; 75% of initial JV stores; phase 1 up to 5 stores; first site Hoxton Street | 2 stores expected by December 2026 | 4 May 2026 release; FY26 release |
| New Zealand DC | Announced May 2026 | 23,000 sqm Auckland DC on a 15-year lease | Live 15 September 2026 | Pharmacy Daily; Sigma website |
| UAE online | October 2025 | E-commerce across the UAE; GCC planned | Operating | Wikipedia summary |
| Owned and exclusive label expansion | Ongoing | 470+ new lines in FY26; sales up 15.0% | Ongoing | FY26 release |
| Store refurbishment | FY26 | 18 CW stores refurbished by franchisees | Ongoing | FY26 presentation |
| Working capital program | FY27 | Each 1-day CCC improvement is worth about A$30m; plans in place | Planned | FY26 presentation |
| Boots evaluation | June 2026 | Preliminary participation in the Boots sale process | Withdrawn 15 June 2026 | ASX via Reuters |
| Sustainability reporting | October 2026 | 2026 Sustainability Report aligned to global standards; Risk, Compliance and Sustainability Committee oversight | Published | TipRanks |
Medium-term targets and guidance
| Target | Value | Source |
|---|---|---|
| Synergies | A$100m a year by FY29 | FY26 release |
| Dividend payout ratio | 50–70% of NPAT | FY26 release |
| Australian store rollout | Consistent with historical cadence (about 13 in 1H27) | FY26 release |
| International store rollout | 19 stores in 1H27, including the UK | FY26 release |
| Earnings guidance | No quantitative FY27 EBIT or NPAT guidance identified. Management's outlook is positive, with continued store expansion and double-digit sales growth expected (FY26 call summary via StockAnalysis). | — |
Products & Services
Australia segment — retail brands (franchised)
| Brand / offering | Description | Target customer | Scale / latest data | Source |
|---|---|---|---|---|
| Chemist Warehouse | Flagship big-box discount pharmacy: everyday low pricing, very wide range, high-volume dispensary | Value-seeking mass-market consumers | 561 Australian CW-branded stores at FY26 (24 added); network sales A$10.2bn, up 15.9%; LFL growth c. 13% | FY26 release / presentation; Yahoo transcript summary |
| My Chemist | Sister banner to Chemist Warehouse (same ownership since 1997); same discount positioning in smaller formats | Mass market | Included in CW-branded network figures (separate count not disclosed) | Market Index; The Nightly |
| Amcal / Amcal+ | Legacy Sigma franchise banner; health-services-oriented community pharmacy | Community / health-services customers | Part of 881 Australian franchise stores (FY25); separate count not disclosed post-merger | FY25 release; ShareCafe |
| Discount Drug Stores (DDS) | Legacy Sigma value banner | Price-sensitive community customers | Count not separately disclosed post-merger | ShareCafe; Motley Fool |
| Guardian, PharmaSave, Chemist King | Legacy Sigma banners (historic) | Community pharmacy | likely consolidated or minor | Motley Fool ticker profile |
| Optometrist Warehouse | Discount optometry format co-located with CW (since February 2023) | Eyecare consumers | Store count not publicly disclosed | Wikipedia summary |
| Chemist Warehouse Online | E-commerce channel. A standalone e-commerce DC was closed and folded into the main network in FY26. | Online shoppers | Online sales not separately disclosed | FY26 presentation |
| Store refurbishment program | Franchisee-funded refits | Network | 18 CW stores refurbished by franchisees in FY26 (18 also cited for 1H26) | FY26 and 1H26 presentations |
Australia segment — product categories and owned label
| Category / offering | Description | Latest data | Source |
|---|---|---|---|
| Dispensary (PBS and private scripts) | Prescription medicines, including GLP-1 weight-loss drugs, which management expects to drive enduring growth with flow-on benefits for adjacent categories | GLP-1 sales cited as a structural uplift in 2H FY25; dilutive to GM% | FY26 release; Macquarie Conference update |
| Vitamins and supplements | Core CW traffic category | — | — |
| Beauty, cosmetics, fragrance | High-margin front-of-store | — | — |
| Owned and exclusive label portfolio | Private and exclusive brands sold through the CW network; described by management as an important investment to support customer value and margin while CW remains "a house of brands" | Sales approaching A$1.0bn (almost 10% of CW network sales), up 15.0%; more than 470 new lines launched in FY26 (400+ in 1H26) | FY26 release; Yahoo transcript summary; Business News Australia |
Individual owned-label brand names are not itemised in the sources reviewed. They are not listed here to avoid inaccuracy.
Australia segment — wholesale and services
| Service | Description | Scale | Source |
|---|---|---|---|
| Full-line pharmaceutical wholesale | Supply of PBS medicines, OTC and front-of-store to more than 3,500 pharmacy customers | 579m+ units in FY26, up 6.5% | ASX profile; FY26 presentation |
| Distribution network | 11 Australian DCs with more than 240,000 sqm aggregate capacity | 600,000+ deliveries a year | FY26 presentation via Investing.com |
| 3PL services | Third-party logistics for manufacturers | Described as an increasingly important margin contributor (FY24) | Legacy Sigma FY24 release |
| CSO distribution | Government-funded obligation to supply PBS medicines nationally | Lower CSO revenue noted in 1H25 | Legacy Sigma 1H25 presentation |
International segment
| Market | Format | Scale | Status | Source |
|---|---|---|---|---|
| New Zealand | Chemist Warehouse stores; new Auckland DC (23,000 sqm, 15-year lease, live 15 September 2026) | c. 70 network stores (1H26) | Mature and growing | Nutraingredients; Pharmacy Daily; Sigma website |
| Ireland | Chemist Warehouse stores | 17 stores (1H26) | Profitable for the first time in FY26 | Nutraingredients; FY26 release |
| UAE (Dubai) | Stores plus online (launched October 2025; GCC expansion planned) | 2 stores (1H26) | Early stage | Nutraingredients; Wikipedia summary |
| China | Bricks-and-mortar CW stores | c. 10 stores (per ASX profile) | Being progressively closed over two years from August 2025 | FY25 release |
| United Kingdom | JV with Greenlight Healthcare (22 London pharmacies); Sigma licenses CW brand and IP and takes 75% of initial JV stores; first site Hoxton Street, east London | 2 stores expected by end of calendar 2026; phase 1 up to 5 stores | Launching | 4 May 2026 release; FY26 release; Ord Minnett |
| Total international | — | International store sales A$1.6bn, up 23.3%; LFL c. 12%; 20 stores opened in FY26; 19 planned for 1H27 | — | FY26 presentation; Business News Australia |
Financial Narrative
Structural caveat
A clean five-year series does not exist. Because of the reverse acquisition, statutory accounts from FY25 onward are those of CWG consolidating Sigma from 12 February 2025. FY25 statutory therefore contains 12 months of CWG and only about 4.5 months of legacy Sigma. Pre-FY25 CWG accounts were private (summary figures appeared in the scheme booklet). Legacy Sigma's own accounts used a January year-end.
Three series are therefore presented:
(A): The merged group on statutory, normalised and pro-forma bases.
(B): Legacy Sigma standalone (January year-ends).
(C): CWG pre-merger data points.
(A) Merged group income statement
Notes and sources:
-
FY26 revenue: A$10.8bn reported (FY26 release). A$10,835m TTM from Kalkine and StockAnalysis.
-
FY26 gross profit A$1,956.9m and 18.1% margin: FY26 presentation; Yahoo transcript summary (A$1.96bn, up 15.2%). FY25 pro-forma gross profit is derived from the 15.2% growth.
-
FY26 normalised EBITDA (derived) = net debt A$663.2m ÷ 0.57x.
-
FY26 statutory EBIT (derived) = statutory EBIT margin 9.75% × revenue.
-
FY25 statutory figures: FY25 release (27 August 2025) and FY26 results information release (statutory PBT A$743.5m; normalisations A$66.9m). Statutory NPAT A$529.9m from Pharmacy Daily, 27 August 2025.
-
FY24 normalised pro-forma EBIT of A$605.5m is from the merger prospectus, as cited in the FY26 release.
-
FY26 statutory NPAT: A$708.7m per the earnings call summary; A$709.2m per StockAnalysis. The difference likely reflects attributable vs total NPAT.
-
FY25 DPS reflects only the post-merger final dividend of 1.3c (FY25 release).
(A) Merged group margins (%)
The FY25 statutory-basis EBIT margin of 13.9% is inflated because CWG standalone (franchisor-level) margins dominate the 12-month base. Legacy Sigma's low-margin wholesale contributed only 4.5 months. The pro-forma series (9.63% to 10.06%) is the economically meaningful comparison. Source: FY26 presentation (statutory 9.75%, normalised 10.06%, pro-forma FY25 9.63%, +43bps).
(B) Legacy Sigma standalone
Notes:
-
Sources: legacy Sigma FY24 release (21 March 2024) and FY25 release (20 March 2025).
-
FY23 figures are derived from the reported FY24 changes (revenue down 9.2%; EBIT up 20.4%).
-
FY25 normalised revenue growth was 50.9%, driven by CWG supply onboarding from 1 July 2024.
-
No final dividend was paid for FY25 (January), as the merger had completed.
These figures illustrate the transformation: legacy Sigma earned roughly a 1% EBIT margin, while the merged group earns roughly 10%.
Half-year progression
1H25 pro-forma revenue is derived from the 14.9% growth rate. Sources: 1H26 release and presentation (26 February 2026); FY26 release. Implied 2H26: revenue c. A$5.3bn; normalised EBIT c. A$507m (derived). Sigma notes the first half is usually seasonally stronger.
Balance sheet
Notes:
-
Sources: FY25 release; 1H26 presentation and Appendix 4D summary (InvestSMART); FY26 release.
-
FY26 equity is derived from Kalkine's price-to-book of 5.94x and market cap of A$29.56bn at A$2.64 (7 October 2026).
-
Kalkine reports net debt of A$1,889.4m and debt/equity of 0.40. This likely includes AASB 16 lease liabilities. The discrepancy against Sigma's A$663.2m is definitional.
-
Total assets, goodwill and intangibles, short/long-term debt split and working capital for FY26 are in the FY26 Annual Report but were not extractable in this research. They are marked not publicly disclosed here. Goodwill and intangibles are known to be very large, reflecting the reverse-acquisition PPA over legacy Sigma's net assets and the CW brand.
Cash flow
Notes:
-
Sources: 1H26 presentation (OCF A$317.4m vs A$428.7m; FCF A$284.6m vs A$462.9m); FY26 presentation via StockWireX (OCF A$574.6m; FCF A$500.4m); FY26 release (capex A$56.7m).
-
Sigma defines FCF as OCF less PPE purchases, plus receipts from lease receivables.
-
Dividends paid are derived: 1H26 = FY25 final 1.3c × ~11.5bn shares; FY26 = 1.3c + 2.0c interim × ~11.5bn shares.
-
Prior-period cash flows are not like-for-like, because FY25 included only 4.5 months of legacy Sigma.
-
No buyback has been announced.
Commentary on trends, inflections and drivers
Revenue. Growth decomposes into three drivers:
-
Australian CW network momentum: LFL c. 13%, plus 24 new stores.
-
GLP-1 prescription volumes, a structural uplift that began in 2H FY25 and that Sigma expects to persist.
-
International store expansion, with revenue up 33%.
The pro-forma revenue CAGR from FY24 cannot be computed reliably because no FY24 pro-forma revenue was disclosed. On EBIT, the pro-forma CAGR from FY24 (A$605.5m) to FY26 (A$1,090.0m) is about 34% a year (derived). This compounding reflects CWG margin expansion (22.3% CWG-level margin in 1H FY25, versus 18.3% a year earlier), internalisation of wholesale margin, and synergies.
Margins. Pro-forma gross margin held flat at 18.1% despite mix dilution from GLP-1s, which are high-value, low-margin scripts. Operating leverage is the main EBIT margin driver. Normalised operating expenses rose 9.9% against revenue growth of 15.5%: A$860.4m in FY26 versus A$782.9m pro-forma FY25 (FY26 presentation). Synergies of A$32.6m were delivered in FY26 (A$13.0m in 1H26), against a target of A$100m a year by FY29. The FY29 target was raised from A$60m in August 2025.
Earnings quality. The statutory-to-normalised gap narrowed sharply. FY25 normalisations totalled A$66.9m at the PBT level; FY26 statutory NPAT of A$708.7m was only about 3% below normalised NPAT of A$732.3m. This is consistent with fading one-off merger costs. Ongoing PPA amortisation will, however, keep statutory below normalised.
Cash. FY26 FCF of A$500.4m equalled about 68% of normalised NPAT. Management highlighted working capital, specifically the 54-day CCC, as an explicit cash lever. The 1H26 OCF decline versus pcp reflected the larger merged working capital base and normalisation of CWG's pre-merger working capital.
Balance sheet. Leverage is conservative at 0.57x net debt to EBITDA and falling. This gives capacity for international expansion, as shown by the Boots evaluation and withdrawal, or for higher distributions. No buyback has been announced.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | What it contains | Key products / services |
|---|---|---|
Australia | Wholesale and distribution to the Chemist Warehouse, My Chemist, Amcal and DDS networks and to independents; franchise income; owned and exclusive label; 3PL; CSO; Australian online | PBS and private prescriptions, OTC, vitamins, beauty, fragrance, personal care; logistics services |
International | Chemist Warehouse stores and online in New Zealand, Ireland, UAE, China (closing) and UK (from 2026) | Retail pharmacy and front-of-store; NZ DC from September 2026 |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY25 | FY26 |
|---|---|---|
Australia revenue (AUD Mn, derived) | 9,063 | 10,414 |
International revenue (AUD Mn) | 317 | 421 |
Group revenue (AUD Mn) | 9,380 | 10,835 |
Australia normalised EBIT (AUD Mn) | 874.3 | 1,034.2 |
International normalised EBIT (AUD Mn, FY25 derived) | 29.2 | 55.8 |
Group normalised EBIT (AUD Mn) | 903.4 | 1,090.0 |
Australia EBIT margin (%) | 9.65 | 9.93 |
International EBIT margin (%, derived) | 9.2 | 13.2 |
Australia gross margin (%) | — | 17.6 |
International gross margin (%) | 27.6 | 30.6 |
Segment Overview — Australia
| Segment | Revenue growth | EBIT growth | % of group revenue | % of group EBIT |
|---|---|---|---|---|
Australia | +14.9% | +18.3% | 96.1% | 94.9% |
International | +33.0% | +91.3% | 3.9% | 5.1% |
Income Statement and Per-Share Data
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
Revenue – statutory (AUD Mn) | — | 6,008.5 | 10,835 |
Revenue – pro-forma comparable (AUD Mn, FY25 derived) | — | 9,380 | 10,835 |
Gross profit (AUD Mn, FY25 pro-forma derived) | — | 1,699 | 1,957 |
Normalised EBITDA (AUD Mn; FY25 statutory basis; FY26 derived) | — | 884.1 | 1,163 |
Normalised EBIT – statutory basis (AUD Mn) | — | 834.5 | 1,090.0 |
Normalised EBIT – pro-forma basis (AUD Mn) | 605.5 | 903.4 | 1,090.0 |
Statutory EBIT (AUD Mn, FY26 derived) | — | — | 1,056 |
Statutory profit before tax (AUD Mn) | — | 743.5 | — |
Statutory NPAT (AUD Mn) | — | 529.9 | 708.7 |
Normalised NPAT (AUD Mn, FY25 pro-forma derived) | — | 598.8 | 732.3 |
Normalised EPS (A cents, FY25 derived) | — | 5.27 | 6.4 |
Statutory EPS basic (A cents) | — | — | 6.2 |
Dividends per share (A cents) | — | 1.3 | 4.0 |
Margin Analysis (%)
| Metric | FY25 | FY26 |
|---|---|---|
Gross margin – pro-forma (%) | 18.1 | 18.1 |
Normalised EBIT margin – pro-forma (%) | 9.63 | 10.06 |
Statutory EBIT margin (%) | — | 9.75 |
Normalised EBIT margin – statutory basis (%, derived) | 13.9 | 10.06 |
Normalised NPAT margin – pro-forma (%, derived) | 6.4 | 6.8 |
Statutory net margin (%, derived) | 8.8 | 6.5 |
Income Statement and Margin Analysis (%)
| Metric | FY23 | FY24 | FY25 |
|---|---|---|---|
Net revenue (AUD Mn, FY23 derived) | 3,659 | 3,322.1 | 4,841.2 |
Statutory EBIT (AUD Mn, FY23 derived) | 19.3 | 23.2 | 21.7 |
Normalised EBIT (AUD Mn) | — | 31.4 | 68.0 |
Normalised NPAT (AUD Mn) | — | 12.7 | — |
Normalised EBIT margin (%) | — | 0.9 | 1.4 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansValuation Snapshot
| Metric | Value | Period | Source |
|---|---|---|---|
CWG statutory revenue (AUD Mn) | 3,090 (prior year 2,990) | FY23 (12 months to 30 June 2023) | CWG accounts, as reported by Market Matters (secondary) |
CW retail network sales (AUD Mn) | 5,154.0 (prior 4,559.4), up 13.0% | 1H FY25 (6 months to 31 December 2024) | CWG trading update, 28 January 2025 |
CWG EBIT (AUD Mn) | 437.9 (prior 324.3), up 35.0% | 1H FY25 | CWG trading update |
CWG EBIT margin (%) | 22.3 (prior 18.3) | 1H FY25 | CWG trading update |
LFL network sales growth (%) | 10.3 (prior 8.9) | 1H FY25 | CWG trading update |
Combined Sigma + CWG EBIT (AUD Mn) | c. 500 | FY23 | Sigma commentary, as reported by Market Matters (secondary) |
Income Statement and Margin Analysis (%) (FY26)
| Metric | 1H25 pro-forma | 1H26 | FY26 |
|---|---|---|---|
Revenue (AUD Mn) | 4,787 | 5,500 | 10,835 |
Normalised EBIT (AUD Mn) | 491.0 | 582.9 | 1,090.0 |
Normalised NPAT (AUD Mn) | 328.9 | 392.0 | 732.3 |
Gross margin (%) | — | 18.3 | 18.1 |
Normalised EPS (A cents) | — | 3.4 | 6.4 |
DPS (A cents) | — | 2.0 | 4.0 |
Balance Sheet and Financial Ratios (x)
| Metric | FY25 | 1H26 | FY26 |
|---|---|---|---|
Cash and equivalents (AUD Mn) | 138.8 | 160.5 | — |
Net debt (AUD Mn, excl. leases) | 752.2 | 635.1 | 663.2 |
Net debt / normalised EBITDA (x) | 0.85 | 0.60 | 0.57 |
Total equity (AUD Mn; FY26 derived) | 4,660 | 4,890 | 4,980 |
Cash Flow
| Metric | 1H25 | FY25 | 1H26 | FY26 |
|---|---|---|---|---|
Operating cash flow (AUD Mn) | 428.7 | — | 317.4 | 574.6 |
Capital expenditure (AUD Mn) | — | — | — | 56.7 |
Free cash flow (AUD Mn) | 462.9 | — | 284.6 | 500.4 |
Dividends paid (AUD Mn, derived) | — | — | 150 | 380 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 |
Margin Analysis (%) and Financial Ratios (x)
| Ratio | FY26 value | Basis / source |
|---|---|---|
ROE (%) | 14.7 | Kalkine TTM. Derived check: statutory NPAT A$708.7m / average equity ~A$4.82bn = 14.7%. |
ROCE (%) | 13.7 | Kalkine TTM |
Debt / equity (x) | 0.40 | Kalkine (likely includes leases) |
Net debt / normalised EBITDA (x) | 0.57 | FY26 release |
Cash conversion cycle (days) | 54.0 (described as having risen); each 1-day improvement is estimated to release c. A$30m of cash | FY26 presentation via StockWireX |
Cash conversion (FCF / normalised NPAT, %) | 68 | Derived: 500.4 / 732.3 |
Dividend payout ratio (%) | 63.0 (target range 50–70% of NPAT) | FY26 presentation / release |
Capex / revenue (%) | 0.5 | Derived |
Revenue by Region and Revenue by Region (%)
| Region | FY25 | FY26 |
|---|---|---|
Australia revenue (AUD Mn) | 9,063 | 10,414 |
International revenue (AUD Mn) | 317 | 421 |
International share of group revenue (%) | 3.4 | 3.9 |
Revenue by Region
| Network | FY25 | FY26 |
|---|---|---|
Australian CW-branded network sales (AUD Mn) | 8,800 | 10,200 |
International store sales (AUD Mn) | 1,300 | 1,600 |
Total CW retail network sales (AUD Mn) | 10,300 | 11,800 |
Country Overview
| Country | Stores (latest) | Trend / commentary | Source |
|---|---|---|---|
Australia (CW-branded) | 561 (FY26); 550 (1H26); 537 implied at FY25 | +24 in FY26; 13 planned for 1H27 | FY26 release; 1H26 release |
Australia (all franchise banners) | 881 (FY25) | Includes Amcal and DDS | FY25 release |
New Zealand | c. 70 (1H26) | Growth market; new DC September 2026 | Nutraingredients |
Ireland | 17 (1H26) | First profitable year in FY26 | Nutraingredients; FY26 release |
UAE | 2 stores plus online | Online launched October 2025 | Nutraingredients; Wikipedia summary |
China | c. 10 (pre-closure) | Closing progressively over two years from August 2025 | ASX profile; FY25 release |
UK | 0 (2 expected by December 2026) | Greenlight JV | FY26 release |
Total international | 97 (1H26); c. 98 cited post-FY26 | 20 opened in FY26, partly offset by China closures | 1H26 release; Business News Australia |
Valuation Snapshot — Last close
| Metric | Value | Source / date |
|---|---|---|
Last close | A$2.80 (15 October 2026); A$2.81 (14 October 2026) | HotCopper; Listcorp |
52-week range | A$2.47 – A$3.20 | ad-hoc-news; StockAnalysis (October 2026) |
FY26 result-day close | A$2.62 (down 7.75%), 27 August 2026 | Kalkine |
Post-Boots-withdrawal close | A$2.80 (up 6.1%), 15 June 2026 | MoneyAM |
1-year performance | About –7% over 12 months to late August 2026 (underperformed the ASX 200) | Motley Fool, 27 August 2026 |
3-year performance | Strongly positive. Shares had risen about 256% from 11 December 2023 (merger announcement) to January 2025. | Motley Fool, January 2025 |
5-year performance | Strongly positive, driven by the merger re-rating. | — |
Beta | 0.32 | StockAnalysis |
Share Price
| Metric | Jun-2025 | Feb-2026 | Jun-2026 | Aug-2026 | Oct-2026 |
|---|---|---|---|---|---|
SIG share price (AUD) | 2.99 | 2.94 | 2.80 | 2.62 | 2.80 |
Valuation Multiples
| Multiple | Sigma | Source |
|---|---|---|
Trailing P/E (statutory) | 41.7–45.6x | StockAnalysis; ad-hoc-news |
Forward P/E | c. 34x | StockAnalysis; Kalkine |
EV/EBITDA (trailing) | 27.8x | Kalkine |
EV/Sales | 2.91x | Kalkine |
Price/Sales | 2.73x | Kalkine |
Price/Book | 5.94x | Kalkine |
Dividend yield | c. 1.5% fully franked | StockAnalysis; Listcorp |
Analyst Ratings & Targets
| Broker | Rating | Target (AUD) | Date | Source |
|---|---|---|---|---|
Consensus (16 analysts) | Buy | 3.20 average | October 2026 | StockAnalysis |
Morgan Stanley | Buy | 3.30 | 21 September 2026 (reiterated 13 October 2026) | ad-hoc-news / Markets Insider |
Macquarie | Buy | 3.20 | 5 October 2026 | ad-hoc-news |
Ord Minnett | Buy | 3.40 | 15 May 2026 | Ord Minnett |
UBS | (Buy implied) | 3.40 | December 2025 | Motley Fool |
Jarden | Overweight | 3.30 | — | FNArena |
Goldman Sachs | Buy | — | — | StockAnalysis news list |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY25 | FY26 |
|---|---|---|
Interim DPS (A cents) | 0 | 2.0 |
Final DPS (A cents) | 1.3 | 2.0 |
Total DPS (A cents) | 1.3 | 4.0 |
Payout ratio (%) | — | 63.0 |
Analyst Conclusions
Management guidance
Sigma did not issue quantitative FY27 earnings guidance. It did set operational markers:
-
13 Australian CW stores in 1H27.
-
19 international stores in 1H27, including 2 UK stores by December 2026.
-
Synergies on track for A$100m a year by FY29.
-
Port Adelaide DC closure in 1Q FY27.
-
Working capital improvement initiatives.
Commentary on the FY26 call pointed to continued double-digit sales growth (FY26 release; StockAnalysis call summary).
Consensus expectations
The average target price of A$3.20 implies about 14% upside from A$2.80. The forward P/E of about 34x against a trailing P/E of about 42–46x implies consensus expects roughly 20–25% EPS growth into FY27 (derived from the multiples).
Bull case
-
Compounding operating leverage. EBIT growth has outpaced revenue growth every period since the merger (FY26: +20.6% vs +15.5%). Another roughly A$67m of synergies is still to come, and DC consolidation continues.
-
Structural demand tailwinds. GLP-1 adoption, LFL growth of 13–15%, and a steady rollout of 24–26 stores a year support high-single to low-double-digit network growth for years.
-
International optionality at low cost. Ireland's breakeven, the New Zealand DC and the capital-light UK licence model could make International a material earnings contributor, with EBIT already up 91% in FY26.
Bear case
-
Valuation leaves no margin for error. At about 28x EV/EBITDA, the stock fell 6–8% on both the 1H26 and FY26 results despite double-digit growth. Expectations are very high.
-
Founder overhang. About 43% of capital became tradable on 27 August 2026. The 2025 sell-downs exceeded A$1.3bn, and further block sales could cap the share price.
-
Margin mix and policy risk. GLP-1s dilute gross margin percentage, the CCC is rising, and PBS or pharmacy regulation could change the economics of both franchise and wholesale.
Key catalysts and monitorables (next 12 months)
| Catalyst | Expected timing |
|---|---|
| 2026 AGM (remuneration vote, LTI approvals, any trading update) | 21 October 2026 |
| UK first store openings (Hoxton Street and a second site) | By December 2026 |
| Port Adelaide DC closure | 1Q FY27 (July–September 2026); confirmation due |
| Founder shareholding notices and any block trades | Ongoing |
| 1H27 results (synergy run-rate, LFL against GLP-1 comps, CCC progress) | Late February 2027 |
| International store rollout (19 in 1H27) and New Zealand DC ramp-up | Through FY27 |
| PBS and pharmacy policy developments | Ongoing |
| Capital management (payout within 50–70%; any buyback) | 1H27 / FY27 results |
Analyst verdict
Sigma Healthcare has, in less than two years, been transformed from a marginal, low-return wholesaler into one of the highest-quality retail franchisors on the ASX. FY26, the first full merged year, delivered on the merger thesis. Revenue reached A$10.8bn (up 15.5%), normalised EBIT A$1.09bn (up 20.6%) and normalised NPAT A$732.3m (up 22.3%). Leverage fell to 0.57x, and free cash flow of A$500m was generated on capex of under A$60m. The Chemist Warehouse format continues to take share, with LFL growth of about 13% on a A$10bn base. Integration is on schedule, and management showed welcome capital discipline by walking away from Boots.
The debate is therefore about price and supply, not quality. A trailing EV/EBITDA of about 28x and a P/E above 40x already discount several years of double-digit compounding. The market's reaction to two successive strong results (down 6–8% on each) shows how little execution premium remains. The release of more than five billion founder shares from escrow creates a persistent overhang, partly offset by Mario Verrocchi's September 2026 on-market purchase. Governance is adequate but not best-in-class, given founder control and a board that, on the composition verified here, lacks an independent majority. The thin 18% gross margin means mix shifts toward high-value scripts must be offset by private label and supplier support.
On balance, Sigma is a structurally advantaged compounder, best owned by long-horizon investors who accept a full multiple. The medium-term value drivers are synergy delivery to A$100m, working capital release of about A$30m per day of CCC, and proof that the UK licence model travels. Near-term share price direction will depend more on founder selling behaviour and the trajectory of GLP-1 comparatives than on fundamentals. Analyst stance: constructive on fundamentals, neutral-to-positive on valuation, with consensus targets of about A$3.20–3.40 implying low-to-mid-teens upside.
Source note: Figures are taken from Sigma Healthcare ASX releases and presentations (FY24–FY26), the Chemist Warehouse Group trading update (January 2025) and the market and news sources named in each table. Figures marked "derived" are arithmetic computations by the analyst from disclosed data.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Since | Background | Independence | Source |
|---|---|---|---|---|---|
Michael Sammells | Non-Executive Chair | Sigma director pre-merger; Chair post-merger | Former Sigma board member; leads merged board | Independent | Forbes (merger documents); escrow release |
Vikesh Ramsunder | CEO & Managing Director | CEO since c. 2022 (Simply Wall St); MD of merged group since February 2025 | B.Com, MBL; led the Sigma turnaround and the CWG supply win and merger | Executive | Simply Wall St; Forbes |
Mario Verrocchi | Executive Director; CEO – Retail | February 2025 | Joined the Gance group in 1982; co-founded MyChemist (1997) and Chemist Warehouse (2000); member of the Risk, Compliance and Sustainability Committee | Executive (founder; c. 22% holder) | Market Index director profile |
Jack Gance | Non-Executive Director | February 2025 | Co-founder; opened the first pharmacy in 1972 | Non-independent (c. 12–14% holder) | Motley Fool director table; AFR |
Damien Gance | Non-Executive Director (Executive Director until 2025) | February 2025 | Pharmacist; joined MyChemist in 1998; first CW franchisee; former Chief Commercial Officer of CWG; stepped down from executive duties in 2025 | Non-independent | Executive changes release (27 August 2025); Motley Fool |
Danielle Di Pilla | Executive Director | February 2025 | CWG Chief People Officer; cousin of Mario Verrocchi | Executive | Forbes |
Annette Carey | Non-Executive Director | Pre-merger Sigma director | Prior Sigma board | Independent | Forbes |
Neville Mitchell | Non-Executive Director | Pre-merger Sigma director | Chair of Fisher & Paykel Healthcare; NED of Sonic Healthcare since September 2017; international healthcare and finance experience | Independent | Motley Fool director profiles |
Chris Roberts | Non-Executive Director | Pre-merger Sigma director | Directorships linked to HMC Capital-managed vehicles, Clarity Pharmaceuticals and the Cochlear Foundation (per profile excerpt) | Independent | Forbes; Motley Fool profile excerpt |
Executive Leadership Team
| Name | Title | Tenure / notes | Source |
|---|---|---|---|
Vikesh Ramsunder | CEO & Managing Director | See above | — |
Mario Verrocchi | CEO – Retail | Since merger | Notice of AGM 2026 |
Mario Tascone | Deputy CEO – Retail | Appointed August 2025 (previously CWG COO); responsible for day-to-day retail operations | Executive changes release; Pharmacy Daily |
Richard Murray | Chief Financial Officer | Appointed after Mark Davis's departure; presented 1H26 results (February 2026) | 1H26 presentation; TipRanks headline |
Mark Davis | Former Group CFO | Gave notice in August 2025; transitioned pending successor | Executive changes release |
Mark Conway | Promoted August 2025 | — | Executive changes release |
Executive Leadership Team by Executive
| Executive | Item | Amount | Period / source |
|---|---|---|---|
Vikesh Ramsunder | Total reported remuneration | A$5.71m | FY25 (Simply Wall St). |
Vikesh Ramsunder | Shares issued under incentive plans | 813,449 shares (A$2.35m value) | 9 January 2026 (Motley Fool director dealings) |
Vikesh Ramsunder | Proposed 2026 LTI | 1,084,167 rights | Notice of AGM 2026 |
Mario Verrocchi | Total reported remuneration | A$396.9k | FY25 (Simply Wall St) |
Mario Verrocchi | Shares issued | 314,021 shares (A$0.91m) | 9 January 2026 |
Mario Verrocchi | Proposed 2026 LTI | 349,060 rights | Notice of AGM 2026 |
Danielle Di Pilla | Shares issued | 141,591 shares (A$0.41m) | 9 January 2026 |
Major Shareholders
| Holder | Shares | % of issued capital | Source / date |
|---|---|---|---|
Mario Verrocchi and associates | 2,555,284,920 | 22.13% | Substantial holder data (InvestSMART); escrow release, 9 July 2026 |
Jack Gance and associates | 1,579,050,058 (substantial notice) / 1,423,948,843 (escrow notice) | 13.67% / c. 12.3% | InvestSMART; escrow release |
Sam Gance and associates | 1,446,864,015 (substantial notice) / 1,326,864,015 (escrow notice) | 12.53% / c. 11.5% | InvestSMART; escrow release |
Damien Gance | Not disclosed precisely (top-5 holder per Simply Wall St) | — | Simply Wall St |
Challenger Limited | Bought 23.4m shares in February 2025; current stake not disclosed | <5% | Simply Wall St |
Institutions (aggregate) | — | c. 6–15% (estimates vary by data vendor) | Simply Wall St |
General public (retail, including former CWG franchisee holders) | — | c. 31–35% | Simply Wall St |
Competitive Landscape
Key Competitors
| Competitor | Segment(s) | Key brands / description | Latest scale | Source |
|---|---|---|---|---|
EBOS Group (ASX/NZX: EBO) | Wholesale; retail pharmacy banners | Symbion (wholesale), TerryWhite Chemmart, Cincotta Chemist; also animal care | FY26 revenue c. 13.5bn (up 9.9%); underlying profit 614m; NPAT 225.2m; community pharmacy revenue 7.1bn; TWC sales 2.9bn. EBOS reports in NZ$; Australian media reported these as "$". | Pharmacy Daily; Motley Fool, 19 August 2026 |
Wesfarmers Health (division of ASX: WES) | Wholesale (former API); retail franchise | Priceline Pharmacy, Soul Pattinson Chemist, Clear Skincare, MediAesthetics, InstantScripts | FY26 revenue A$6,474m (up 9.1%); earnings A$76m (up 18.8%); Priceline network sales up 12.7%; 23 new stores | Wesfarmers FY26 results; Business News Australia |
Woolworths Group | Front-of-store OTC, vitamins, beauty | Supermarket health and beauty aisles | Category-level data not disclosed | — |
Coles Group | Front-of-store OTC, vitamins, beauty | Supermarket health and beauty | — | — |
Blooms The Chemist | Retail pharmacy franchise | Community pharmacy banner | Private; not disclosed | — |
National Pharmacies | Retail pharmacy (member-owned, SA/VIC) | Mutual-owned pharmacy chain | — | — |
Good Price Pharmacy Warehouse | Discount pharmacy retail | Direct discount-format competitor | Private; not disclosed | — |
Pharmacy 4 Less / Direct Chemist Outlet | Discount pharmacy | Discount formats | Private; not disclosed | — |
Amazon Australia; online pharmacies (e.g., Your Discount Chemist) | E-commerce health and beauty | Online marketplaces, including Temu-listed pharmacy sellers | — | Pharmacy Daily |
Mecca / Sephora | Beauty and cosmetics | Prestige beauty | — | — |
Green Cross Health (NZ) | NZ retail pharmacy | Unichem, Life Pharmacy | — | — |
Bargain Chemist (NZ) | NZ discount pharmacy | Direct NZ discount competitor | — | — |
Boots, Superdrug, Tesco, Sainsbury's (UK) | UK pharmacy and health & beauty | Incumbents a CW UK entry must compete with | Boots has about 1,800 stores | City AM; Nutraingredients |
Boots Ireland, Hickey's, McCabes (Ireland) | Irish pharmacy retail | Incumbents | — | — |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | Sigma Healthcare | EBOS Group | Wesfarmers Health |
|---|---|---|---|
Revenue (local m) | 10,835 | 13,487 | 6,474 |
Revenue growth (%) | 15.5 | 9.9 | 9.1 |
EBIT / earnings (local m) | 1,090 | — | 76 |
EBIT margin (%) | 10.1 | — | 1.2 |
Net profit (local m) | 709 | 225.2 | — |



